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Abstract
BACKGROUND: Colorectal cancer is one of the most common cancers worldwide and leading cause of cancer 
related deaths. Connexins are integral membrane proteins that form channels between adjacent cells. Gap 
junction intercellular communication plays essential roles in tissue homoeostasis and regulation of cell growth and 
differentiation. Connexins can act as either tumor suppressors or tumor promoters. The human connexin protein 
family contains 21 members, of which the most widely studied is connexin 43 (Cx 43).
OBJECTIVES: Investigation of immunohistochemical expression of Cx 43 in cases of colorectal adenoma and 
carcinoma and correlation of this expression with the clinico-pathological aspects of the tumors.
MATERIALS AND METHODS: Seventy formalin fixed paraffin embedded BC tissue sections were randomly 
collected. All the available data were collected from the patients’ reports. The paraffin blocks were sectioned 
and stained with hematoxylin and eosin stains for histologic evaluation. Additional sections were immunostained 
with Cx 43.
RESULTS: Cx 43 expression was negative in all studied cases.
CONCLUSION: Cx 43 is a tumor suppressor that is lost early in colorectal carcinogenesis and can be considered as 
potential target for cancer chemoprevention and chemotherapy aiming at restoration of normal connexin expression 
and functional gap junctions.
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Introduction
Colorectal cancer (CRC) is one of the most 
common cancers worldwide. More than 1 million new 
cases were reported annually resulting in about 600,000 
deaths worldwide per year [1]. Worldwide, CRC is the 
second most common cancer in women and the third 
most common in men [2].
In Egypt, colorectal carcinoma accounts for 
6.48% of all cancers according to the National Cancer 
Institute Cairo University [3].
Loewenstein and Kanno were the first 
to propose the idea that gap junction intercellular 
communication (GJIC) regulates tumor growth more 
than 50 years ago in a study, in which they demonstrated 
the loss of electrical coupling occurring in rat liver 
tumors [4]. Connexins are integral membrane proteins 
that form channels between adjacent cells. GJIC plays 
essential roles in tissue homoeostasis and regulation of 
cell growth and differentiation [5]. In addition, connexins 
form functional channels at the non-junctional areas of 
the plasma membrane, these so-called hemichannels 
provide a communication pathway between the 
intracellular and extracellular milieus that is an important 
in autocrine and paracrine signaling [6]. 
Connexins can act as either tumor suppressors 
or tumor promoters depending on the isoform, cancer 
stage, and tissue. In addition to the emerging prognostic 
value of connexins in cancer, several studies indicate 
that connexin targeting might have considerable 
therapeutic implications [7], [8]. Cancer cells often 
display a loss of GJIC due to the dysregulation of 
connexin expression at multiple levels [9].
The human connexin protein family contains 21 
members, of which the most widely studied is connexin 
43 (Cx 43) [5].
Several studies reported that Cx 43 
acts as tumor suppressor that is downregulated 
in colorectal carcinoma they are considered as 
potential targets for cancer chemoprevention and 
chemotherapy [10], [11], [12], [13], [14].
Materials and Methods
A total of 70 formalin fixed, paraffin embedded 
tissue sections; divided as follow: 20 cases of 
colorectal adenoma and 50 cases of carcinoma were 
randomly collected from endoscopic and colectomy 
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specimens, blind of their clinico-pathological, and 
immunohistochemical data. The cases were collected 
from the Pathology Department at the Kasr El-Aini 
hospital in the time period between May 2018 and 
February 2019.
The data collected from the pathology reports 
of the cases included age and sex of patient, tumor size, 
type, and the degree of dysplasia as regard cases of 
adenoma. Regarding carcinoma cases, data collected 
included age and sex of patient, size of tumor, as well 
as the lymph node status.
The paraffin blocks of the tumor tissue were 
serially sectioned at 4 μm thickness, stained with 
routine hematoxylin and eosin stains for pathological 
examination. The tumors were histologically typed 
according to the latest available World Health 
Organization recommendations [15].
Tumors histological grading was performed 
according to the World Health Organization 
recommendations [2]. Tumors staging was performed 
using the TNM staging system and the cases were 
further divided into prognostic stages [16]. Modified 
Duke’s staging was also performed [17].
The tumor sections were also examined for the 
presence of lymphovascular invasion and perineural 
invasion.
For immunostaining, additional serial sections 
were prepared from the paraffin blocks and mounted 
on charged slides. Heat mediated antigen retrieval was 
performed with citrate buffer pH 6 in automated water 
bath (Dako PT link, PT101). Sections were stained 
for anti-connexin 43 antibody (Rabbit Polyclonal Anti-
Connexin 43/GJA1 antibody [EPR21153] ab217676) 
obtained from Abcam and used at a dilution of 1:250. 
Immunohistochemical staining was performed in an 
autostainer (Dako Autostainer Link 48) using a polymer-
based detection system (Dako EnVision™ FLEX, 
K8000). Diaminobenzidine was used as chromogen 
and hematoxylin as counterstain. Sections of normal 
human prostate tissue were used as positive control 
according to the manufacturer’s recommendation.
The immunohistochemical staining was 
analyzed. The percentage of positively stained cells 
in normal, adenomatous, and cancerous tissues 
was assessed according to a 3-point scale: 0 (<10% 
positively stained cells), 1+ (10–50% positively stained 
cells), and 2+ (>50% positively stained cells). The 
results of Cx 43 immunostaining were expressed as 
Cx 43-positive (level of expression 1+ and 2+) and Cx 
43-negative (level of expression 0) [18].
A substrate of cases was also stained 
immunohistochemically against β-catenin and Cyclin 
D1 using the same above methods.
Microsoft Excel 2010 was used for data entry 
and the Statistical Package for the Social Sciences 
(SPSS version 21) was used for data analysis. Simple 
descriptive statistics (arithmetic mean and standard 
deviation) used for summary of quantitative data and 
frequencies used for qualitative data.
Finally, microscopic photos were captured 
using a digital camera attached to an Olympus 
microscope model BX 51.
Results
This study is a retrospective study including 
70 randomly selected cases; 20 cases of colorectal 
adenoma and 50 cases of carcinoma obtained from 
endoscopic and colectomy specimens. The cases 
were collected from the Kasr Al-Aini Hospital in the 
time period between May 2018 and February 2019. 
The clinico-pathological data, histological examination, 
and immunohistochemical results are summarized in 
Table 1.
In the present study, connexin 43 (Cx 43) was 
evaluated in colorectal adenoma and carcinoma cases. 
Sections from normal prostate gland were stained 
in the same runs with our colorectal adenoma and 
carcinoma cases, as positive control as instructed by 
the primary antibody’s manufacturer. It was strongly 
and consistently expressed in the basal cells of normal 
human prostate glands. However, it was not expressed 
in all of colorectal adenoma and carcinoma cases.
Discussion
In the present study, connexin 43 (Cx 43) was 
evaluated in colorectal adenoma and carcinoma cases. 
Sections from normal prostate gland were stained 
in the same runs with our colorectal adenoma and 
carcinoma cases, as positive control as instructed by 
the primary antibody’s manufacturer. It was strongly 
and consistently expressed in the basal cells of normal 
human prostate glands (Figure 1c). However, it was not 
expressed in all of colorectal adenoma and carcinoma 
cases (Figure 1d and e). Hence, we suggest that Cx 43 
may act as tumor suppressor gene and its expression 
is lost early in colorectal carcinogenesis.
It was only expressed focally in normal mucosa 
adjacent to adenocarcinoma (Figure 1a and b) that 
was in concordance with Nemeth et al. [19], Dubina 
et al. [20] and Kanczuga-Koda et al. [21] where Cx 43 
was sparsely distributed in the human colonic epithelial 
cells. The notion that connexins are able to form gap 
junctions in normal colonic mucosa is further supported 
by Western blot analysis of protein extracts from normal 
colon tissue [22].
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regulating the assembly of Cx 43 into gap junctions 
or Cx 43 endocytosis and postendocytic sorting [13]. 
Furthermore, loss of Cx 43 expression was significantly 
correlated with shorter relapse-free survival and overall 
survival. Loss of Cx 43 further identified among Sage 
I and Stage II patients with reduced relapse-free and 
overall survival. However, this study was carried on cell 
lines and they combine both immunohistochemistry 
and Western blot techniques. They concluded that Cx 
43 acts as a CRC tumor suppressor and that loss of Cx 
43 expression during CRC development is associated 
with reduced patient survival [22].
Furthermore, Ismail et al. demonstrated that 
Western blotting using anti-Cx 43 antibody indicated 
that the expression of Cx 43 was significantly 
downregulated in 75% of colon cancer samples and 
immunohistochemical analysis of the tissue samples 
confirmed the downregulation of the Cx 43. Cx 43 
downregulation showed significant association (p < 0.05) 
with the histological type and tumor invasion properties 
of the cancer. They suggested that loss of Cx 43 may 
be an important event in colon carcinogenesis and 
tumor progression, providing significant insights about 
Table 1: Clinico-pathologic features and Cx 43 expression
Parameter n (%) Cx 43 (positive 
expression)
Cx 43 (negative 
expression)
Adenoma cases 20 (28.6) 0 (0) 20 (28.6)
Age
(27–76 years, mean 59.8±11.83)
Sex
Male 14 (70)
Female 6 (30)
Site
Left colon 11 (55)
Right colon 4 (20)
Rectum 5 (25)
Size
<2 cm 17 (85)
>2 cm 3 (15)
Histologic grade
Low grade dysplasia 14 (70)
High grade dysplasia 6 (30)
Type
Tubular 11 (55)
Tubulovillous 4 (20)
Serrated 5 (25)
Carcinoma cases 50 (71.4) 0 (0) 0 (71.4)
Age
(30–75 years, mean 54±11.62)
Sex
Male 22 (44)
Female 28 (56)
Site
Left colon 19 (38)
Right colon 19 (38)
Rectum 12 (24)
Size
(3–12 cm, mean 5.7±1.97)
Histologic types
Adenocarcinoma 41 (82)
Mucoid carcinoma 9 (18)
Histologic grade of adenocarcinoma
Grade I 0 (0)
Grade II 30 (73)
Grade III 11 (27)
T stage
T1 0 (0)
T2 4 (8)
T3 36 (72)
T4 10 (20)
N stage
N1 18 (36)
N2 16 (32)
N3 16 (32)
M stage
M0 49 (98)
M1 1 (2)
Stage
Stage I 3 (6)
Stage II 15 (30)
Stage III 31 (62)
Stage IV 1 (2)
Modified Duke’s class
A 0 (0)
B1 3 (6)
B2 15 (30)
C1 23 (46)
C2 8 (16)
D 1 (2)
Lymphovascular invasion
Positive 16 (32)
Negative 34 (68)
Perineural invasion
Positive 18 (36)
Negative 32 (64)
In concordance to our results, Sirnes et al. 
have shown that Cx 43 is either absent or aberrantly 
localized in colon cancer cell lines and colorectal 
carcinomas, which is associated with loss of GJIC. They 
studied a cohort of 674 colorectal carcinoma patients. 
About 63% of patients had weak or no expression of 
Cx 43 in tumors [22]. Although some colon cancer cell 
lines express Cx 43 at the protein level in vitro, they 
usually do not form gap junctions, probably because 
of aberrant regulation of the intracellular trafficking of 
Cx 43. The mechanisms underlying such impaired Cx 
43 trafficking remain to be elucidated, but may involve 
dysregulation of the signaling pathways involved in 
Figure 1: (a and b) Cx 43 expression in normal colonic mucosa, 
(c) Cx 43 expression in basal cell layer of prostatic glands “positive 
control,” (d) negative Cx 43 expression in colonic adenocarcinoma, 
(e) negative Cx 43 expression in mucoid carcinoma, (f) positive 
β-catenin membranous staining in adenocarcinoma
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f
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the tumor suppressive properties of the Cx 43 and its 
potential as a diagnostic marker for colon cancer [14].
Dubina et al. also considered that Cx 43 
acts as tumor suppressor since their function or 
expression is frequently aberrant in tumor cells. They 
have demonstrated that connexin 43 is specifically 
and quite frequently mutated in human colon sporadic 
adenocarcinomas. All tumor-associated mutations led to 
a shift of reading frame causing premature stop codons 
and truncation of the multifunctional carboxyl- terminal 
domain of the protein. Expression of mutated connexin 
43 proteins was restricted to invasive structures 
of tumors. These findings suggest that mutational 
alterations of connexin 43 are involved in advanced 
stages of progression of human colon cancer toward 
malignancy [20].
Since the interaction between connexins of 
adjacent cells is not strong enough to maintain the 
cytoplasmic membranes of the neighboring cells 
together and to form the canal, the formation and 
maintenance of gap junctions require the presence 
of cell adhesion molecules [23], [24]. So substrate of 
cases was immunohistochemically stained with the 
adhesion molecule β-catenin. The majority of cases 
were negative apart from a focal positive area where 
focal membranous staining was noted between the 
tumor cells (Figure 1f). The correlation between Cx 43 
and β-catenin; being both were downregulated in our 
work strengthen our conclusion that Cx 43 has tumor 
suppressor properties being lost in our cases. This 
finding was similar to Kanczuga-Koda et al. who found 
a statistically significant positive correlation between 
β-catenin and Cx 43 in colorectal carcinoma cases [21].
Cx 43 was also shown to participate in cell 
cycle regulation [25], [26]. Cyclin D1 is a protein 
required for progression through the G1 phase of the 
cell cycle. During the G1 phase, it is synthesized rapidly 
and accumulates in the nucleus and is degraded as the 
cell enters the S phase [27]. A substrate of cases was 
stained with Cyclin D1 and they found to be negative, 
this finding was approximate to Qi et al. who found 
significant correlation between the protein expression 
rates of Cyclin D1 and Cx 43 (p < 0.05) in rectal cancer 
specimens [28].
Decreased gap junctional communication 
and reduced connexin expression were subsequently 
observed in several cancer types. Moreover, many 
growth factors, oncogenes and tumor promoters are 
potent inhibitors of GJIC [13].
Strengthening our results, several lines of 
experimental evidence indicate that connexins may 
act as tumor suppressors. First, restoration of GJIC 
by transfection of connexin genes into tumorigenic 
cells has been shown to normalize growth in vitro and 
in vivo [29], [30], [31], [32]. Second, downregulation of 
connexins by small interfering RNA has been found to 
result in more aggressive growth of cancer cells [32]. 
Third, knock-out of connexin genes in mice results 
in increased susceptibility to chemical or radiation-
induced tumor formation [33], [34], [35]. Collectively, 
these observations are in concordance with our results 
in which the connexins may act as tumor suppressors, 
and they are considered as potential targets for cancer 
chemoprevention and chemotherapy [10], [11], [12].
Although several studies have shown that 
connexins are downregulated in colorectal carcinomas, 
some studies; in contrast to, our results have observed 
enhanced connexin expression. Han et al. stated that Cx 
43 cytoplasmic expression increased progressively in the 
colonic adenocarcinoma sequence in both the epithelial 
and stromal components. In the epithelial component, 
Cx 43 was expressed lower in Stage I adenocarcinomas 
compared to Stage III/IV. In addition, Cx 43 was relatively 
increased in the adenocarcinoma at the invasive tumor 
front in all stages. Cytoplasmic expression of Cx 43 
was frequently observed in colonic cancer cells. In 
addition, we found that the level of Cx 43 expression was 
significantly associated with higher AJCC Stage III/IV but 
did not have impact on the histological grading [36].
Another study showed higher Cx 43 expression 
in adenomas compared to healthy colonic mucosa 
suggesting an active role of Cx 43 in the process of 
carcinogenesis. Moreover, higher Cx 43 expression 
was found in the colonic mucosa surrounding advanced 
colorectal adenoma [37]. Stromal Cx 43 expression in 
CRC was found to be higher in more advanced CRC 
showing that it is a possible indicator of metastatic 
potential of colorectal adenocarcinoma [18].
Regarding the role of Cx 43 in other different 
tumors, many studies also reported its tumor suppressor 
effects. Ableser et al. suggest that Cx 43 can act as a 
tumor suppressor during melanoma tumorigenesis [38]. 
Solan et al. who studied the role of Cx 43 in pancreatic 
adenocarcinoama cell lines show decreased or altered 
connexin expression and/or localization [39]. Silencing 
connexin 43 induces cell cycle entry and invasion in 
non-neoplastic mammary epithelial cells [40]. Connexin 
43 also suppresses lung cancer stem cells [41]. 
Yet different organs but they stated that it has tumor 
suppressor properties.
Regarding role of other connexins in CRC, 
patients with high levels of Cx 26 in the primary tumor 
have been reported to have a higher probability 
of developing lung metastasis. Furthermore, lung 
metastases, but not lymph node or liver metastases, 
have a higher level of Cx 26 expression than the 
corresponding primary colorectal tumor. Cx 26 
localizes both in intracellular compartments and at the 
plasma membrane in the metastatic cells, indicating a 
possible role for GJIC during metastasis. Thus, Cx 26 
is a promising therapeutic target, particularly for CRC 
patients who develop lung metastasis [42].
The finding that several connexin isoforms are 
expressed in colonic tissue, along with the fact that they 
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function in a redundant manner, makes it challenging to 
understand the roles of the specific connexin isoform in 
the normal colonic mucosa and in CRC pathogenesis. 
It will also be important to define which isoforms are 
expressed at the protein level in the normal colonic 
epithelium and to obtain a better understanding of how 
their expression changes during CRC progression [13].
The fact that connexins may be involved 
in both tumor suppression and tumor progression 
should be carefully evaluated before connexins can be 
considered as targets in cancer therapy. On the one 
hand, restoration of connexin expression and functional 
gap junctions may result in reduced tumor growth; on 
the other hand, increasing connexin expression may 
in other circumstances leads to increased cancer cell 
invasion. A central step toward determining whether 
connexins could represent beneficial targets in CRC 
prevention and therapy will be to obtain a better 
understanding of the molecular basis underlying their 
dysregulation during disease development.
Conclusion
Cx 43 is a tumor suppressor that is lost early 
in colorectal carcinogenesis and can be considered 
as potential target for cancer chemoprevention and 
chemotherapy aiming at restoration of normal connexin 
expression and functional gap junctions.
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